Day One Biopharmaceuticals lands $130m Series B

Day One Biopharmaceuticals, a provider of targeted therapies for children and adults with cancer, has raised $130 million in Series B financing.

10 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles